Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Abdullah A. Osman, David M. Neskey, Panagiotis Katsonis, Ameeta A. Patel, Alexandra M. Ward, Teng Kuei Hsu, Stephanie Hicks, Thomas O. McDonald, Thomas J. Ow, Marcus Ortega Alves, Curtis R. Pickering, Heath D. Skinner, Mei Zhao, Eric M. Sturgis, Merrill S. Kies, Adel El-Naggar, Federica Perrone, Lisa Licitra, Paolo Bossi, Marek KimmeMitchell J. Frederick, Olivier Lichtarge, Jeffrey N. Myers

Research output: Contribution to journalArticle

Abstract

TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

Original languageEnglish (US)
Pages (from-to)1205-1215
Number of pages11
JournalCancer Research
Volume75
Issue number7
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Platinum
Mutation
Cisplatin
Therapeutics
Patient Selection
Drug Therapy
Survival
Genes
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Osman, A. A., Neskey, D. M., Katsonis, P., Patel, A. A., Ward, A. M., Hsu, T. K., ... Myers, J. N. (2015). Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Research, 75(7), 1205-1215. https://doi.org/10.1158/0008-5472.CAN-14-2729

Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. / Osman, Abdullah A.; Neskey, David M.; Katsonis, Panagiotis; Patel, Ameeta A.; Ward, Alexandra M.; Hsu, Teng Kuei; Hicks, Stephanie; McDonald, Thomas O.; Ow, Thomas J.; Alves, Marcus Ortega; Pickering, Curtis R.; Skinner, Heath D.; Zhao, Mei; Sturgis, Eric M.; Kies, Merrill S.; El-Naggar, Adel; Perrone, Federica; Licitra, Lisa; Bossi, Paolo; Kimme, Marek; Frederick, Mitchell J.; Lichtarge, Olivier; Myers, Jeffrey N.

In: Cancer Research, Vol. 75, No. 7, 01.04.2015, p. 1205-1215.

Research output: Contribution to journalArticle

Osman, AA, Neskey, DM, Katsonis, P, Patel, AA, Ward, AM, Hsu, TK, Hicks, S, McDonald, TO, Ow, TJ, Alves, MO, Pickering, CR, Skinner, HD, Zhao, M, Sturgis, EM, Kies, MS, El-Naggar, A, Perrone, F, Licitra, L, Bossi, P, Kimme, M, Frederick, MJ, Lichtarge, O & Myers, JN 2015, 'Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients', Cancer Research, vol. 75, no. 7, pp. 1205-1215. https://doi.org/10.1158/0008-5472.CAN-14-2729
Osman, Abdullah A. ; Neskey, David M. ; Katsonis, Panagiotis ; Patel, Ameeta A. ; Ward, Alexandra M. ; Hsu, Teng Kuei ; Hicks, Stephanie ; McDonald, Thomas O. ; Ow, Thomas J. ; Alves, Marcus Ortega ; Pickering, Curtis R. ; Skinner, Heath D. ; Zhao, Mei ; Sturgis, Eric M. ; Kies, Merrill S. ; El-Naggar, Adel ; Perrone, Federica ; Licitra, Lisa ; Bossi, Paolo ; Kimme, Marek ; Frederick, Mitchell J. ; Lichtarge, Olivier ; Myers, Jeffrey N. / Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. In: Cancer Research. 2015 ; Vol. 75, No. 7. pp. 1205-1215.
@article{62b90ab1488847cca4e360ef8b828958,
title = "Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients",
abstract = "TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.",
author = "Osman, {Abdullah A.} and Neskey, {David M.} and Panagiotis Katsonis and Patel, {Ameeta A.} and Ward, {Alexandra M.} and Hsu, {Teng Kuei} and Stephanie Hicks and McDonald, {Thomas O.} and Ow, {Thomas J.} and Alves, {Marcus Ortega} and Pickering, {Curtis R.} and Skinner, {Heath D.} and Mei Zhao and Sturgis, {Eric M.} and Kies, {Merrill S.} and Adel El-Naggar and Federica Perrone and Lisa Licitra and Paolo Bossi and Marek Kimme and Frederick, {Mitchell J.} and Olivier Lichtarge and Myers, {Jeffrey N.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-14-2729",
language = "English (US)",
volume = "75",
pages = "1205--1215",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

AU - Osman, Abdullah A.

AU - Neskey, David M.

AU - Katsonis, Panagiotis

AU - Patel, Ameeta A.

AU - Ward, Alexandra M.

AU - Hsu, Teng Kuei

AU - Hicks, Stephanie

AU - McDonald, Thomas O.

AU - Ow, Thomas J.

AU - Alves, Marcus Ortega

AU - Pickering, Curtis R.

AU - Skinner, Heath D.

AU - Zhao, Mei

AU - Sturgis, Eric M.

AU - Kies, Merrill S.

AU - El-Naggar, Adel

AU - Perrone, Federica

AU - Licitra, Lisa

AU - Bossi, Paolo

AU - Kimme, Marek

AU - Frederick, Mitchell J.

AU - Lichtarge, Olivier

AU - Myers, Jeffrey N.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

AB - TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=84930967437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930967437&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2729

DO - 10.1158/0008-5472.CAN-14-2729

M3 - Article

C2 - 25691460

AN - SCOPUS:84930967437

VL - 75

SP - 1205

EP - 1215

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -